Merck & Co. Inc. MRK on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence ...

After winning an initial U.S. nod in July 2023, Beyfortus has gone on to do gangbusters for Sanofi and AZ, growing total sales 9.5% last year for a total haul of 1.78 billion euros (roughly $2.1 ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...

Sanofi has replaced chief executive Paul Hudson with the head of German drugmaker Merck KGaA, after the French drugmaker ...

Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...

Rochester, Minn.-based Mayo Clinic and pharmaceutical giant Merck are teaming up to leverage AI for drug discovery and ...

Technology is changing the way pharmaceutical companies discover and develop new drugs. For Matt Studney, who joined Merck as a chemical engineer, technology changed the course of his career. In 2017, ...

Merck & Co., Inc. is rated a Buy due to robust asset portfolio, strong shareholder return, and buybacks. Learn more about MRK stock here.

Little new information was offered at a public meeting Tuesday evening regarding the ongoing closure of Merck’s Cherokee Plant in Riverside.

The Pennsylvania Department of Environmental Protection has not received complaints regarding Merck's Cherokee Plant for more than a decade.

By Atharva Singh and Arasu Kannagi Basil Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% ...